50 related articles for article (PubMed ID: 24927872)
21. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH.
Yoon N; Do IG; Cho EY
APMIS; 2014 Sep; 122(9):755-60. PubMed ID: 24372629
[TBL] [Abstract][Full Text] [Related]
22. Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer.
Tafe LJ; Steinmetz HB; Allen SF; Dokus BJ; Tsongalis GJ
J Clin Pathol; 2015 Apr; 68(4):306-8. PubMed ID: 25576545
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study.
Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ
J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715
[TBL] [Abstract][Full Text] [Related]
25. Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study.
van der Logt EM; Kuperus DA; van Setten JW; van den Heuvel MC; Boers JE; Schuuring E; Kibbelaar RE
PLoS One; 2015; 10(4):e0123201. PubMed ID: 25844540
[TBL] [Abstract][Full Text] [Related]
26. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
[TBL] [Abstract][Full Text] [Related]
27. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
Hicks DG; Tubbs RR
Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
[TBL] [Abstract][Full Text] [Related]
29. HER2 assessment by silver in situ hybridization: where are we now?
Sanguedolce F; Bufo P
Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
[TBL] [Abstract][Full Text] [Related]
30. A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer.
Wesoła M; Jeleń M
Adv Clin Exp Med; 2015; 24(5):899-903. PubMed ID: 26768643
[TBL] [Abstract][Full Text] [Related]
31. [Companion diagnostics with FISH assay (HER2, ALK)].
Hiraoka M
Rinsho Byori; 2014 Apr; 62(4):390-8. PubMed ID: 25022069
[TBL] [Abstract][Full Text] [Related]
32. Primary mucinous cystadenocarcinoma of the breast with amplification of the HER2 gene confirmed by FISH - case report and review of the literature.
Kucukzeybek BB; Yigit S; Sari AA; Rezanko T; Durak E; Sadullahoglu C
Pol J Pathol; 2014 Mar; 65(1):70-3. PubMed ID: 25119013
[TBL] [Abstract][Full Text] [Related]
33. What Therapeutic Biomarkers in Gastro-Esophageal Junction and Gastric Cancer Should a Pathologist Know About?
Kumarasinghe MP; Houghton D; Allanson BM; Price TJ
Surg Pathol Clin; 2023 Dec; 16(4):659-672. PubMed ID: 37863558
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
